Asset Details
Do you wish to reserve the book?
Adjuvant Pembrolizumab in Resected Stage III Melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant Pembrolizumab in Resected Stage III Melanoma
Do you wish to request the book?
Adjuvant Pembrolizumab in Resected Stage III Melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant Pembrolizumab in Resected Stage III Melanoma
2018
Overview
To the Editor:
In the past 2 years, Eggermont et al. have reported the findings of two landmark trials of adjuvant immunotherapy for stage III melanoma: the European Organization for the Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab
1
and the EORTC 1325 trial of pembrolizumab (May 10 issue).
2
Both trials suggest that adjuvant immunotherapy had a smaller effect on preventing locoregional recurrence than on preventing distant metastases. Neither article provides details on regional recurrence in patients at high risk for this event, such as those with macroscopic involvement of large or multiple lymph nodes or those with . . .
Publisher
Massachusetts Medical Society
